StockData
Oncotelic Therapeutics, Inc. logo

Oncotelic Therapeutics, Inc. (OTLC) stock

OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.02+0.00 (+11.45%)

Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –

Oncotelic Therapeutics cash

Cash and short-term investments held at the end of each period.

Oncotelic Therapeutics's cash was $186.01K at Jun 30, 2026. For fiscal 2025 it was $88.86K, up 3.2% from the year before. Over ten years it grew -43.6% a year on average. The highest annual figure on record is $30.03M in fiscal 2014.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$88.86K+3.2%
FY2024Dec 31, 2024$86.13K-49.5%
FY2023Dec 31, 2023$170.41K-29.4%
FY2022Dec 31, 2022$241.45K-57.5%
FY2021Dec 31, 2021$568.77K+20.0%
FY2020Dec 31, 2020$474.02K+478.3%
FY2019Dec 31, 2019$81.96K+3181.2%
FY2018Dec 31, 2018$2.50K-99.8%
FY2017Dec 31, 2017$1.12M-90.7%
FY2016Dec 31, 2016$12.00M-56.0%
FY2015Dec 31, 2015$27.29M-9.1%
FY2014Dec 31, 2014$30.03M+328.7%
FY2013Dec 31, 2013$7.01M+41.6%
FY2012Dec 31, 2012$4.95M-50.4%
FY2011Dec 31, 2011$9.97M+116.7%
FY2010Dec 31, 2010$4.60M-67.0%
FY2009Dec 31, 2009$13.93M-23.8%
FY2008Dec 31, 2008$18.28M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$186.01K+134.9%
Q1 FY2026Mar 31, 2026$63.61K-26.1%
Q4 FY2025Dec 31, 2025$88.86K-40.4%
Q2 FY2025Jun 30, 2025$88.02K+21.9%
Q1 FY2025Mar 31, 2025$79.17K-58.1%
Q4 FY2024Dec 31, 2024$86.13K-49.5%
Q3 FY2024Sep 30, 2024$149.02K-44.4%
Q2 FY2024Jun 30, 2024$72.22K-60.3%
Q1 FY2024Mar 31, 2024$188.99K-0.8%
Q4 FY2023Dec 31, 2023$170.41K-29.4%
Q3 FY2023Sep 30, 2023$268.02K+5.6%
Q2 FY2023Jun 30, 2023$181.87K-54.5%
Q1 FY2023Mar 31, 2023$190.44K+94.5%
Q4 FY2022Dec 31, 2022$241.45K-57.5%
Q3 FY2022Sep 30, 2022$253.88K+225.2%
Q2 FY2022Jun 30, 2022$399.77K-13.3%
Q1 FY2022Mar 31, 2022$97.91K-88.2%
Q4 FY2021Dec 31, 2021$568.77K+20.0%
Q3 FY2021Sep 30, 2021$78.08K-94.3%
Q2 FY2021Jun 30, 2021$461.29K-30.2%
Q1 FY2021Mar 31, 2021$830.72K+352.9%
Q4 FY2020Dec 31, 2020$474.02K+478.3%
Q3 FY2020Sep 30, 2020$1.36M+8305.5%
Q2 FY2020Jun 30, 2020$660.90K+684.2%
Q1 FY2020Mar 31, 2020$183.44K-8.3%
Q4 FY2019Dec 31, 2019$81.96K+3181.2%
Q3 FY2019Sep 30, 2019$16.21K-98.5%
Q2 FY2019Jun 30, 2019$84.27K-95.7%
Q1 FY2019Mar 31, 2019$200.00K-14.2%
Q4 FY2018Dec 31, 2018$2.50K-99.8%
Q3 FY2018Sep 30, 2018$1.06M-44.5%
Q2 FY2018Jun 30, 2018$1.97M-60.7%
Q1 FY2018Mar 31, 2018$233.00K-97.2%
Q4 FY2017Dec 31, 2017$1.12M-90.7%
Q3 FY2017Sep 30, 2017$1.91M-88.3%
Q2 FY2017Jun 30, 2017$5.00M-74.1%
Q1 FY2017Mar 31, 2017$8.30M–
Q4 FY2016Dec 31, 2016$12.00M–
Q3 FY2016Sep 30, 2016$16.28M–
Q2 FY2016Jun 30, 2016$19.34M–

More Oncotelic Therapeutics figures

See a number that looks wrong?